[1]赖璐华,李玉兰,黄秋菊,等.有营养风险的2型糖尿病周围神经病变患者的临床特征研究[J].医学信息,2022,35(17):120-122.[doi:10.3969/j.issn.1006-1959.2022.17.032]
　LAI Lu-hua,LI Yu-lan,HUANG Qiu-ju,et al.Clinical Characteristics of Type 2 Diabetic Peripheral Neuropathy Patients with Nutritional Risk[J].Journal of Medical Information,2022,35(17):120-122.[doi:10.3969/j.issn.1006-1959.2022.17.032]
点击复制

有营养风险的2型糖尿病周围神经病变患者的临床特征研究()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
35卷
期数:
2022年17期
页码:
120-122
栏目:
临床研究
出版日期:
2022-09-01

文章信息/Info

Title:
Clinical Characteristics of Type 2 Diabetic Peripheral Neuropathy Patients with Nutritional Risk
文章编号:
1006-1959（2022）17-0120-03
作者:
赖璐华; 李玉兰; 黄秋菊; 等
（柳州市人民医院内分泌科1，营养科2，广西 柳州 545006）
Author(s):
LAI Lu-hua; LI Yu-lan; HUANG Qiu-ju; et al.
(Department of Endocrinology1,Department of Nutrition2,Liuzhou People’s Hospita,Liuzhou 545006,Guangxi,China)
关键词:
糖尿病周围神经病变; 2型糖尿病; 营养风险
Keywords:
Diabetic peripheral neuropathy; Type 2 diabetes mellitus; Nutritional risk
分类号:
R587.2
DOI:
10.3969/j.issn.1006-1959.2022.17.032
文献标志码:
A
摘要:
目的 了解有营养风险的2型糖尿病周围神经病变患者的临床特征。方法 采用营养风险筛查2002（NRS2002）对469例2型糖尿病周围神经病变患者进行营养风险筛查，根据评分结果分为有营养风险组122例和无营养风险组347例。比较两组体重指数（BMI）、血红蛋白（HB）、血清前白蛋白（PA）、血清白蛋白（ALB）、总胆固醇（TC）、甘油三酯（TG）、低密度脂蛋白胆固醇（LDL-C）、高密度脂蛋白胆固醇（HDL-C）、胱抑素C（CysC）、血尿酸（UA）、糖化血红蛋白（HbA1c）、空腹C肽（FCP）、餐后2小时C肽（2hCP）、住院时间、住院费用，分析2型糖尿病周围神经病变患者发生营养风险的危险因素。结果 469例2型糖尿病周围神经病变患者的营养风险发生率为26.01%，男性的发生率为28.22%，女性的发生率为23.68%，差异无统计学意义（P＞0.05）；有营养风险组年龄、HbA1c高于无营养风险组，BMI、TG、UA、HB、ALB、PA、FCP、2hCP低于无营养风险组，差异有统计学意义（P＜0.05）；多因素Logistic非条件回归分析显示，HbA1c是2型糖尿病周围神经病变患者发生营养风险的危险因素，BMI和ALB是保护因素（P＜0.05）；有营养风险组住院时间、住院费用均高于无营养风险组，差异有统计学意义（P＜0.05）；Spearman相关性分析显示营养风险与住院时间、住院费用呈正相关（r=0.147、0.158，P＜0.05）。结论 有营养风险组的2型糖尿病周围神经病变患者可能导致不良临床结局。血糖控制差、BMI和ALB偏低的2型糖尿病周围神经病变患者容易出现营养风险，而营养风险可导致患者住院时间、住院费用增加。
Abstract:
Objective To investigate the clinical characteristics of type 2 diabetic peripheral neuropathy patients with nutritional risk.Methods Nutritional risk screening 2002 ( NRS2002 ) was used to screen the nutritional risk of 469 patients with type 2 diabetic peripheral neuropathy.According to the score, they were divided into nutritional risk group (122 cases) and non-nutritional risk group (347 cases). The body mass index (BMI), hemoglobin (HB), serum prealbumin (PA), serum albumin (ALB), total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), cystatin C (CysC), blood uric acid (UA), glycosylated hemoglobin (HbA1c), fasting C-peptide (FCP), 2-hour postprandial C-peptide (2hCP), hospitalization time and hospitalization expenses were compared between the two groups. The risk factors of nutritional risk in patients with type 2 diabetic peripheral neuropathy were analyzed.Results The incidence of nutritional risk in 469 patients with type 2 diabetic peripheral neuropathy was 26.01%, the incidence of male was 28.22%, and the incidence of female was 23.68%, the difference was not statistically significant (P>0.05). The age and HbA1c in the nutritional risk group were higher than those in the non-nutritional risk group, and the BMI, TG, UA, HB, ALB, PA, FCP and 2 hCP were lower than those in the non-nutritional risk group (P<0.05). Multivariate Logistic regression analysis showed that HbA1c was a risk factor for nutritional risk in patients with type 2 diabetic peripheral neuropathy, BMI and ALB were protective factors (P<0.05). The hospitalization time and hospitalization expenses of the nutritional risk group were higher than those of the non-nutritional risk group, and the difference was statistically significant (P<0.05). Spearman correlation analysis showed that nutritional risk was positively correlated with hospitalization time and hospitalization expenses (r=0.147,0.158,P<0.05).Conclusion Patients with type 2 diabetic peripheral neuropathy in the nutritional risk group may lead to adverse clinical outcomes. Patients with type 2 diabetic peripheral neuropathy with poor blood glucose control, low BMI and ALB are prone to nutritional risks, which can lead to increased hospitalization time and hospitalization costs.

参考文献/References:

[1]中华医学会糖尿病学分会,中国医师协会营养医师专业委员会.中国糖尿病医学营养治疗指南（2013)[J].中华糖尿病杂志,2015,7(2):73-88.[2]Vinik AI.Diabetic Sensory and Motor Neuropathy[J].N Engl J Med,2016,374(15):1455-1464. [3]Pop-Busui R,Boulton AJ,Feldman EL,et al.Diabetic neuropathy: a position statement by the American Diabetes Association[J].Diabetes Care,2017,40(1):136-154.[4]袁丽,白亚菲,杨海波,等.加巴喷丁联合高能红光治疗痛性糖尿病周围神经病变患者的疗效观察[J].广西医学,2019,41(9):1086-1090.[5]van Nooten F,Treur M,Pantiri K,et al.Capsaicin 8% patch versus oral neuropathic pain medications for the treatment of painful diabetic peripheral neuropathy:a systematic literature review and network meta-analysis[J].Clin Ther,2017,39(4):787-803.[6]钱荣立.关于糖尿病的新诊断标准与分型[J].中国糖尿病杂志,2000,8(1):5-6.[7]中华医学会糖尿病学分会.中国2型糖尿病防治指南(2020年版)[J].中华糖尿病杂志,2021,13(4):315-409.[8]Cederholm T,Barazzoni R,Austin P,et al.ESPEN guidelines on definitions and terminology of clinical nutrition[J].Clin Nutr,2017,36(1):49-64.[9]Schuetz P,Fehr R,Baechli V,et al.Individualised nutritional support in medical inpatients at nutritional risk: a randomised clinical trial[J].Lancet,2019,393(10188):2312-2321.[10]崔红元,朱明炜,陈伟,等.中国老年住院患者营养状态的多中心调查研究[J].中国老年医学杂志,2021,40(3):364-369.[11]周锦,高娉,马宁,等.住院病人营养风险筛查及营养支持对临床结局影响的研究[J].肠外与肠内营养,2017,24(1):13-17.[12]潘素琼,陈晓,陆媚英,等.2型糖尿病住院患者456例营养风险筛查分析[J].广西医学,2016,38(5):681-683.[13]孔建华,张洁,滑莹莹,等.营养风险筛查在老年糖尿病肾病患者营养评估中的应用[J].中国临床保健杂志,2017,20(1):58-60.[14]Liu XX,Xu YY,An MM,et al.The risk factors for diabetic peripheral neuropathy: A meta-analysis[J].PLoS One,2019,14(2):e0212574.[15]汪毓诚,何毓箐,吴琦.营养风险筛查在评估肥胖伴糖尿病患者中的应用[J].河北医药,2021,43(11):3614-3617.[16]孙艳,吴智勇,徐勇霞,等.住院老年2型糖尿病合并痛性神经病变患病率及危险因素[J].中国老年学杂志,2020,40(17):3614-3617.[17]陈士光,赖璐华,邓珊珊,等.2型糖尿病周围神经病变患者IGF-l水平变化及其临床意义[J].现代医院,2021,21(5):807-809.[18]常琦,吴元波,任明山,等.2型糖尿病患者周围神经病变相关危险因素分析[J].中国神经免疫学和神经病学杂志,2015,22(5):342-346.[19]朱慧君,马瑞,孙淑娟,等.北京市某社区2型糖尿病患者并发周围神经病变的调查及影响因素分析[J].中国慢性病预防与控制,2017,25(12):902-904.[20]郭阳阳.2型糖尿病患者BMI水平与血管并发症的关系[D].厦门:福建医科大学,2017.

相似文献/References:

[1]黄德斌,章臻翊,章 婷,等.2型糖尿病患者亚临床甲状腺功能减退与白蛋白尿的关系研究[J].医学信息,2018,31(02):88.[doi:10.3969/j.issn.1006-1959.2018.02.030]
　HUANG De-bin,ZHANG Zhen-yi,ZHANG Ting,et al.Relationship between Subclinical Hypothyroidism and Albuminuria in Patients with Type 2 Diabetes Mellitus[J].Journal of Medical Information,2018,31(17):88.[doi:10.3969/j.issn.1006-1959.2018.02.030]
[2]邓婷婷,王亚洲,张 红.口福怡稻治疗2型糖尿病的临床效果研究[J].医学信息,2018,31(03):116.[doi:10.3969/j.issn.1006-1959.2018.03.039]
　DENG Ting-ting,WANG Ya-zhou,ZHANG Hong.Clinical Study on the Treatment of Type 2 Diabetes Mellitus with Kou Fuyi Dao[J].Journal of Medical Information,2018,31(17):116.[doi:10.3969/j.issn.1006-1959.2018.03.039]
[3]曹岚,侯瑞田,王福慧,等.Lp-PLA2血小板相关因子与2型糖尿病合并高血压病的 相关性研究[J].医学信息,2018,31(05):3.[doi:10.3969/j.issn.1006-1959.2018.05.002]
　CAO Lan,HOU Rui-tian,WANG Fu-hui,et al.Study on the Correlation between Lp-PLA2 Platelet-associated Factors and Type 2 Diabetes Mellitus Complicated with Hypertension[J].Journal of Medical Information,2018,31(17):3.[doi:10.3969/j.issn.1006-1959.2018.05.002]
[4]龚玉萍.中药足浴联合硫辛酸治疗糖尿病周围神经病变临床分析[J].医学信息,2018,31(05):18.[doi:10.3969/j.issn.1006-1959.2018.05.006]
　GONG Yu-ping.Clinical Analysis of Traditional Chinese Medicine Foot Bath Combined with Lipoic Acid in the Treatment of Diabetic Peripheral Neuropathy[J].Journal of Medical Information,2018,31(17):18.[doi:10.3969/j.issn.1006-1959.2018.05.006]
[5]靳雪芹,邓正聪.代谢综合征与肿瘤关系的研究进展[J].医学信息,2018,31(05):35.[doi:10.3969/j.issn.1006-1959.2018.05.014]
　JIN Xue-qin,DENG Zheng-cong.Research Progress on the Relationship between Metabolic Syndrome and Tumor[J].Journal of Medical Information,2018,31(17):35.[doi:10.3969/j.issn.1006-1959.2018.05.014]
[6]刘 洪.地特胰岛素或甘精胰岛素联合使用口服药物治疗2型糖尿病疗效及对体重的影响分析[J].医学信息,2018,31(09):135.[doi:10.3969/j.issn.1006-1959.2018.09.042]
　LIU Hong.Effect of Insulin Detemir or Insulin Glargine Combined with Oral Medication on Type 2 Diabetes Mellitus and its Influence on Body Weight[J].Journal of Medical Information,2018,31(17):135.[doi:10.3969/j.issn.1006-1959.2018.09.042]
[7]郭云飞,王亚柱,刘 超,等.血浆致动脉硬化指数与冠心病合并2型糖尿病的相关性分析[J].医学信息,2022,35(09):108.[doi:10.3969/j.issn.1006-1959.2022.09.027]
　GUO Yun-fei,WANG Ya-zhu,LIU Chao,et al.Correlation Between Plasma Arteriosclerosis Index and Coronary Heart Disease Complicated with Type 2 Diabetes Mellitus[J].Journal of Medical Information,2022,35(17):108.[doi:10.3969/j.issn.1006-1959.2022.09.027]
[8]徐晨曦.达格列净联合DPP-4抑制剂与二甲双胍对血糖控制不佳2型糖尿病患者血糖及脂代谢的影响[J].医学信息,2022,35(09):165.[doi:10.3969/j.issn.1006-1959.2022.09.042]
　XU Chen-xi.Effects of Daglitazone Combined with DPP-4 Inhibitor and Metformin on Blood Glucose and Lipid Metabolism in Patients with Type 2 Diabetes Mellitus with Poor Glycemic Control[J].Journal of Medical Information,2022,35(17):165.[doi:10.3969/j.issn.1006-1959.2022.09.042]
[9]余 佳.早期胰岛素强化治疗对初诊2型糖尿病患者血糖控制效果及颈动脉粥样硬化进展的影响[J].医学信息,2022,35(10):140.[doi:10.3969/j.issn.1006-1959.2022.10.034]
　YU Jia.Effect of Early Intensive Insulin Therapy on Blood Glucose Control and Progression of Carotid Atherosclerosis in Newly Diagnosed Type 2 Diabetic Mellitus Patients[J].Journal of Medical Information,2022,35(17):140.[doi:10.3969/j.issn.1006-1959.2022.10.034]
[10]张剑君.2型糖尿病参与血管衰老的机制[J].医学信息,2022,35(11):37.[doi:10.3969/j.issn.1006-1959.2022.11.011]
　ZHANG Jian-jun.The Mechanism of Type 2 Diabetes Mellitus in Vascular Aging[J].Journal of Medical Information,2022,35(17):37.[doi:10.3969/j.issn.1006-1959.2022.11.011]
[11]陈国兰,黄秋菊,李玉兰.2型糖尿病周围神经病变与血清促甲状腺激素关系的研究[J].医学信息,2019,32(06):86.[doi:10.3969/j.issn.1006-1959.2019.06.027]
　CHEN Guo-lan,HUANG Qiu-ju,LI Yu-lan.Study on the Relationship between Type 2 Diabetic Peripheral Neuropathy and Serum Thyroid Stimulating Hormone[J].Journal of Medical Information,2019,32(17):86.[doi:10.3969/j.issn.1006-1959.2019.06.027]

更新日期/Last Update: 1900-01-01